ProQR Therapeutics N.V.(PRQR) says enrollment has started in study PQ-010-001, a global Phase 1b clinical study of QR-010, an investigational RNA therapeutic designed to repair the genetic mutation in the mRNA of cystic fibrosis (CF) patients due to the DF508 mutation.
PRQRProQR Therapeutics NV
$1.994.19%
Edge Rankings
Momentum38.59
Growth94.92
Quality-
Value47.13
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in